CDER Dispute Resolution Process Gained Prominence In 2007
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's formal dispute resolution process had a higher profile in 2007 than previous years, suggesting that the rising number of multiple action letters and increasingly vocal criticism of FDA intransigence likely have contributed to the trend of more - or more public - formal appeals
You may also be interested in...
FDA Denies Gilead’s Appeal Of Aztreonam Lysine “Complete Response” Letter
Gilead has not yet discussed with FDA whether ongoing studies will be sufficient for resubmission of the inhaled antibiotic for use by cystic fibrosis patients.
FDA First Cycle Approval Rate Is Silver Lining In Cloud Of Dismal NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved.
FDA First Cycle Approval Rate Is Silver Lining In Cloud Of Dismal NME Count
Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved.